Benzinga | Feb 2, 2021 09:10AM EST

Arena Pharmaceuticals Completes Full Enrollment Of Etrasimod Phase 3 ELEVATE UC 52 Trial

-- Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC)

-- Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022

-- Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response or intolerance to conventional or advanced therapies

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis. The trial enrolled 433 study participants in approximately 40 countries globally.

"Completion of UC 52 enrollment is the first important step in a comprehensive clinical program designed to potentially provide broad access and improve outcomes in patients with moderately-to-severely active ulcerative colitis. We thank our investigators, clinical site coordinators and especially the participants in the trial for enabling us to meet this important milestone," said Paul Streck, M.D., Senior Vice President, Clinical Development and Chief Medical Officer at Arena. "We expect topline data from both the ELEVATE UC 52 and UC 12 trials in Q1 2022, and we remain focused on successful clinical trial execution with careful attention to data integrity and the safety of the trial participants."